A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2017
Price : $35 *
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 01 Dec 2017 Status changed from active, no longer recruiting to completed.
- 28 Nov 2017 Planned primary completion date changed from 6 Nov 2017 to 4 Dec 2017.
- 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.